Virbac UK Veterinary

Explore our interactive training modules

  • Module 1: Mastering Mast Cell Tumours

  • Module 2: Treating Canine Mast Cell Tumours

  • Module 3: STELFONTA®

  • Module 4: FNA and cytology

Webinars

Fundamentals of Mast Cell Tumour Management with Gerry Polton MA VetMB MSc(Clin Onc) DipECVIM-CA(Oncology) MRCVS

Mast cell tumours are famously variable in their appearance, so how do you know when to suspect one? And what do you do when you do suspect one to make sure you don’t make it worse? Maybe you’ve successfully removed a mast cell tumour and then you are invited to select from a panel of curiously entitled additional tests; how do you know whether a test is indicated? And what do you do when you get the results? Which mast cell tumours are cured by local therapy and which ones need additional medical treatment?

Join guest speaker Gerry Polton (RCVS & European Specialist in Veterinary Oncology) on Tuesday 17th May for what he hopes will be an engaging walk through these fundamental questions as they relate to mast cell tumour management in dogs. Neil Mottram BSc BVSc MRCVS, Technical Product Manager will then be discussing the latest intratumoural injection from Virbac, STELFONTA®. This session will start with a ‘how to’ section followed with case studies, showing delegates that ‘seeing is believing’. STELFONTA® is an innovative and effective intratumoural treatment for mast cell tumours - the most common cutaneous neoplasm in dogs. Its active ingredient, Tigilanol tiglate, has a unique mode of action causing destruction of the mast cell tumour and there is complete resolution in 75% of cases after just one treatment. Treatment results in complete tumour destruction, leaving behind a healthy granulating wound which heals by secondary intention with minimal intervention within just 4-6 weeks.

Note: view in full screen for best viewing experience

Webinars

STELFONTA: Seeing Is Believing with Pamela D. Jones DVM

In this webinar Dr Pam Jones will introduce you to the unique mode of action of tigilanol tiglate, review the efficacy data behind this new product and demonstrate how this highly innovative yet simple treatment can be used to provide a high tumour elimination rate, wound healing and a speedy return to a good quality of life for the pet.

Dr Pamela Jones underwent her veterinary training in the United States at Colorado State University. She completed a one year rotating internship in small animal medicine and surgery followed by a three year oncology residency and a two-year residency in radiation oncology. She is board-certified by the American College of Veterinary Internal Medicine in medical oncology and by the American College of Veterinary Radiology in radiation oncology. She has enjoyed specialty practice in the southwestern United States and has served in several capacities in the pharmaceutical industry.

Note: view in full screen for best viewing experience

Mast Cell Tumours: An Update with Dr Owen Davies
 

In this webinar Dr Owen Davies will review mast cell tumours and diagnostic approaches before appraising the current treatment options.

Dr Owen Davies is an RCVS and American recognised specialist in veterinary oncology. Before his residency at the Royal Veterinary College he spent 9 years in general practice, including mixed, small animal, private and charity work. He is a member of the Australian and New Zealand College of Veterinary Scientists (chapter of small animal medicine), a diplomat of the ACVIM (oncology) and holds a master’s degree based on research into canine lymphoma. Owen currently works at Highcroft Veterinary Referrals in Bristol.

 

Note: view in full screen for best viewing experience

A GP approach to work up canine mast cell tumours - Presented by Sara Verganti Dip ECVIM-CA (Onc) MSc (Clin Onc) MRCVS
 
Sara’s webinar takes a GP perspective on mast cell tumours; their clinical presentation, how to achieve a diagnosis. With guidance on staging followed by an overview of treatment options including the latest novel intratumoural injection, STELFONTA®.
 

Note: view in full screen for best viewing experience

The histopathology report and proliferative markers: what they mean for your patients - Presented by Roberta Rasotto DVM PhD DipECVP MRCVS
 
Roberta’s session focuses on the histopathological features of mast cell tumours. Discussion will include MCT prognostic factors with a focus on proliferation markers and grading evaluation.
 

Note: view in full screen for best viewing experience

What Cytology Can Tell You - Presented by Francesco Cian DVM DipECVCP FRCPath MRCVS
 
Francesco will talk delegates through MCT cytology; their cytological presentation, diagnostic challenges and discussion around cytological grading and staging.
 

Note: view in full screen for best viewing experience

Virbac Oncology Summit 2020

Browse by chapter

  • Chapter 01: Seeing is believing

  • Chapter 02: Discovery of a new compound from the Australian rainforest

  • Chapter 03: Let’s have a closer look

  • Chapter 04: Efficacy of an intra-tumoral treatment of canine MCTs with Tigilanol tiglate

  • Chapter 05: Durability of the clinical response to intratumoral injection of Tigilanol tiglate in dogs

  • Chapter 06: Practical STELFONTA

  • Chapter 07: Let’s have a closer look

  • Chapter 08: Tolerability of Tigilanol tiglate

  • Chapter 09: What do we know from Tigilanol tiglate

  • Chapter 10: What do we learn on the management of MCTs by GPs in Europe

  • Chapter 11: How do I manage MCTs with Tigilanol tiglate

  • Chapter 12: Perspectives on Tigilanol tiglate?

  • Chapter 13: Conclusion